Omeros completes rolling submission of Biologics License Application (BLA) to FDA for narsoplimab for treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA)

Narsoplimab targets mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of complement. The Eueopean Medicines Agency has granted orphan drug designation to narsoplimab for treatment of HSCT and of primary IgA nephropathy.

Source:

Biospace Inc.